Palmetto Retina Center的动态

NIH researchers have identified AKT2-related lysosome dysfunction as a key factor in the formation of drusen, a hallmark of dry age-related macular degeneration (AMD). This discovery points to a new potential therapeutic target for AMD, offering hope for future treatments for this common cause of vision loss. Learn more: https://brnw.ch/21wOcBR #RetinaCare #EyeHealth #Ophthalmology #VisionCare #EyeCare #RetinaSpecialists #patientcentricity

NIH researchers have identified AKT2-related lysosome dysfunction as a key factor in the formation of drusen, a hallmark of dry age-related macular degeneration (AMD). This discovery points to a new potential therapeutic target for AMD, offering hope for future treatments for this common cause of vision loss. Learn more: https://brnw.ch/21wNrb3 #RetinaCare #EyeHealth #Ophthalmology #VisionCare #EyeCare #RetinaSpecialists #patientcentricity

NIH researchers have identified AKT2-related lysosome dysfunction as a key factor in the formation of drusen, a hallmark of dry age-related macular degeneration (AMD). This discovery points to a new potential therapeutic target for AMD, offering hope for future treatments for this common cause of vision loss. Learn more: https://lnkd.in/g6USh6_B #RetinaCare #EyeHealth #Ophthalmology #VisionCare #EyeCare #RetinaSpecialists #patientcentricity

NIH researchers have identified AKT2-related lysosome dysfunction as a key factor in the formation of drusen, a hallmark of dry age-related macular degeneration (AMD). This discovery points to a new potential therapeutic target for AMD, offering hope for future treatments for this common cause of vision loss. Learn more: https://brnw.ch/21wNmH4 #RetinaCare #EyeHealth #Ophthalmology #VisionCare #EyeCare #RetinaSpecialists #patientcentricity

NIH researchers have identified AKT2-related lysosome dysfunction as a key factor in the formation of drusen, a hallmark of dry age-related macular degeneration (AMD). This discovery points to a new potential therapeutic target for AMD, offering hope for future treatments for this common cause of vision loss. Learn more: https://brnw.ch/21wNboM #RetinaCare #EyeHealth #Ophthalmology #VisionCare #EyeCare #RetinaSpecialists #patientcentricity

I am excited to announce that our article titled “Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic” has been published in Multiple Sclerosis Journal! ?? In this work, we explore implementation of the blood-based biomarker Neurofilament Light in the real-world and the effects such a novel biomarker could have on daily practice in the MS clinic. You can read the full paper here: https://lnkd.in/eRXnhZRs. #MultipleSclerosis #Neurofilaments

Results of the first real-world evaluation of use of NfL in a MS center clinic! What did we show? - Clinical decisions changed in 19.3% of cases post-disclosure, particularly in context “new symptoms” and in patients with higher sNfL levels. - In case of low sNfL levels: certainty in the clinical decision increased, while expectation of MRI activity decreased. - Motivation to measure NfL was highest in context “differential diagnosis”; perceived value and urgency were highest in context “new symptoms”. - There was a strong interest to get the result within less than one-two days after the clinical visit. The last finding is in my opinion an important support for implementation of NfL tests with quick turnaround times!

Rather than a one-size-fits-all blood test that looks for a single pathology, NeuroDex is commercializing a novel scientific approach, based on the study of extracellular vesicles – that can decipher “mixed pathology” in dementia and lead to a more personalized treatment plan. #HealthTransformer #HealthMoonshot #AlzMoonshot Meet Erez Eitan, PhD, and NeuroDex ?? https://ow.ly/JxXE50U3BZi

Read the new case story: https://lnkd.in/dzTbTuYX, how Uniklinik RWTH Aachen aims to unlock personalized medical solutions for chronic neuropathic pain with Sophion Bioscience’s Qube 384 solution. “????’???? ?????????????? ?????? ?????????????? ?????????????? ???? ?????????????? ???????????????? ???? ?????? ??????????????-?????????? ???????????? ???????????????? ??????1.7 ?????? ??????1.8, ???? ???? ?????????????? ?????????? ???????? ?????????? ???????????????????? ?????????????? ?????????? ???????????? ?????????????????? ????????????????????,” ???????????????? Angelika Lampert. “???? ???????????????? ???? ???????? ?????? ???????? ???? ?? ???????? ???? ???????????? ?????????? ?????????? ?????????????????????????????????? ???????? ?? ???????? ???????????? ?????????? ?????????????? ?????? ???????? ???? ?????????? ???? ?????? ?????????????? ?????????? ???? ?????? ???????? ?????? ?????? ?????? ?????????????? ???? ??????????????????????????.” ????’?? ?? ?????????????? ???????? ??????????, ?????? ????’?? ???????? ???????????????????? ???????? ??????????????????. “???? ?????? ???????????? ???????? ???? ???????????????????? ?????? ???????????????? ???? ?? ????????????????, ?????? ???????? ???? ???????? ???? ???????? ?????????? ?????? ???? ???????? ????????????????????????,” ???????? Angelika Lampert. At Uniklinik RWTH Aachen, a pioneering initiative called ?????????????????????????????? is underway. Using patients’ own sensory neurons derived from induced pluripotent stem cells, the Aachen team aims to understand the underlying mechanisms of chronic pain, and they are now using Sophion Bioscience’s Qube 384 solution to investigate therapeutic possibilities. #UniklinikRWTHAachen #Qube384 #PatchClamp #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion

So interesting how technological advances potentially can aid in meeting the future needs of pain patients.